Nystatin Oral Suspension, USP 100,000 units per mL

Manufacturer
Akorn | Akorn Operating Company LLC
Effective date
2022-03-15
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
6
Source
legacy-cache
Hydrated at
2026-08-01 22:06:02

Label at a glance#

ProductNystatin
Active ingredientNYSTATIN
Label structure10 sections

Indications and uses

Nystatin oral suspension, USP is indicated for the treatment of infections of the oral cavity caused by Candida albicans .

Dosage and administration

Infants: 2 mL (200,000 units) four times daily (1 mL in each side of mouth). Pediatric patients and adults: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). NOTE: Limited clinical studies in neonates, including premature and low-birth weight neonates, indicate that 1 mL (100,000 units) four times daily is effective. Local treatment should be continued at least 48 hour...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Nystatin is obtained from Streptomyces noursei. It is known to be a mixture, but the composition has not been completely elucidated. Nystatin A is closely related to amphotericin B. Each is a macro-cyclic lactone containing a ketal ring, an all-trans polyene system, and a mycosamine (3-amino-3-deoxyrhamose) moiety.

Its structural formula is:

Image of Structural Formula
Image of Structural Formula

C47H75NO17 M.W. 926.13

Nystatin oral suspension, USP is a cherry-mint flavored, ready-to-use suspension. Each mL of nystatin oral suspension, USP contains 100,000 units of nystatin in a vehicle containing 50% w/v sucrose with the following inactive ingredients: alcohol (less than 1% v/v), carboxymethylcellulose sodium, cherry flavor, citric acid, glycerin, peppermint flavor, purified water, and sodium citrate. Citric acid and/or sodium hydroxide may be used to adjust pH (5.3-7.5).

PRESERVATIVES ADDED: Methylparaben 0.12%, Propylparaben 0.03%

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Nystatin acts by binding to sterols in the cell membrane of the fungus with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin is absorbed very sparingly following oral administration, with no detectable blood levels when given in the recommended doses.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Nystatin oral suspension, USP is indicated for the treatment of infections of the oral cavity caused by Candida albicans.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Nystatin is contraindicated in patients with a history of hypersensitivity to nystatin or any of the suspension components.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Discontinue treatment with nystatin if sensitization or irritation is reported during use.

Nystatin is not effective in the treatment of systemic mycoses since it is not significantly absorbed from the gastrointestinal tract.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Patient should be advised to retain nystatin in the mouth as long as possible and to continue its use for at least 2 days after symptoms have subsided.

There should be no interruption or discontinuation of the medication until the prescribed course of treatment is completed, even though symptomatic relief may occur within a few days.

If symptoms of local irritation develop, the physician should be notified immediately.

Laboratory Tests

LABORATORY TESTS SECTION

If there is a lack of therapeutic response, appropriate microbiological studies (e .g., KOH smears and/or cultures) should be repeated to confirm the diagnosis of candidiasis and rule out other pathogens before instituting another course of therapy.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. In mice exposed to nystatin 50 mg/kg by injection, an increased incidence of chromosomal aberrations, consisting primarily of chromatid breaks, was observed in bone marrow cells. However, there have been no studies to determine the mutagenicity of orally-administered nystatin or its effects on fertility in males or females.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Pregnancy Category C

SPL UNCLASSIFIED SECTION

Teratogenicity studies have not been conducted with nystatin. It is also not known whether nystatin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin should be given to a pregnant woman only if clearly needed.

Nonteratogenic Effects

NONTERATOGENIC EFFECTS SECTION

In one rat reproductive study, nystatin was administered orally to pregnant rats in single doses of 100, 500, or 3000 mg/kg on the ninth day of gestation, or as multiple doses of 500 mg/kg/day on gestation days 1-20, 1-4, 7-10, 11-14, or 15-18. It was found that nystatin had a slight abortive effect when used during the whole period of pregnancy. No abnormalities were seen in surviving fetuses. Although no adverse effects or complications have been attributed to the use of intra-vaginal nystatin in neonates born to women treated during pregnancy, no similar studies evaluating complications of oral nystatin have been conducted.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

To report SUSPECTED ADVERSE REACTIONS, contact Hi-Tech Pharmacal Co., Inc. at 1-800-262-9010 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Gastrointestinal symptoms including diarrhea, gastrointestinal distress, nausea, vomiting and burning of the mouth have been reported. Hypersensitivity reactions including rash, pruritus, and anaphylactoid reaction have also been reported.

OVERDOSAGE

OVERDOSAGE SECTION

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Infants: 2 mL (200,000 units) four times daily (1 mL in each side of mouth).

Pediatric patients and adults: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth).

NOTE: Limited clinical studies in neonates, including premature and low-birth weight neonates, indicate that 1 mL (100,000 units) four times daily is effective.

Local treatment should be continued at least 48 hours after perioral symptoms have disappeared and/or cultures returned to normal. It is recommended that the drug be retained in the mouth as long as possible before swallowing.

HOW SUPPLIED

HOW SUPPLIED SECTION

Nystatin Oral Suspension USP, 100,000 units per mL, is available as a yellow, milky, ready-to-use suspension with a cherry-mint flavor in the following sizes:

60 mL bottles (with child-resistant calibrated dropper)

473 mL bottles

A 2 mL calibrated dropper with 1 mL calibrations is provided with the 60 mL container.

SHAKE WELL BEFORE USING.

Storage: Store between 15°-30°C (59°-86°F). PROTECT FROM FREEZING.

Dispense in a tight, light resistant container when dispensing from the original container.

KEEP OUT OF REACH OF CHILDREN.

Manufactured by:

Hi-Tech Pharmacal Co., Inc.

Amityville, NY 11701

Rev. 587:02 08/17

Package/Label Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

label
label

AKORN

NDC 50383-587-16

Nystatin Oral Suspension, USP

100,000 units per mL

Rx only

SHAKE WELL BEFORE USING


WARNING- NOT FOR INJECTION

473 mL

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50383-587-16ML - Milliliter50383-587aaac5690-86c2-4a39-8258-14113544d74312012-07-24
50383-587-66ML - Milliliter50383-5873534ff37-b61d-4e86-8aa7-40546e3c223b12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
NYSTATINACTIVE INGREDIENTBDF1O1C72E2
NYSTATINACTIVE MOIETYBDF1O1C72E2
ALCOHOLINACTIVE INGREDIENT3K9958V90M2
ANHYDROUS CITRIC ACIDINACTIVE INGREDIENTXF417D3PSL2
CARBOXYMETHYLCELLULOSE SODIUMINACTIVE INGREDIENTK679OBS3112
GLYCERININACTIVE INGREDIENTPDC6A3C0OX2
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9T2
PROPYLPARABENINACTIVE INGREDIENTZ8IX2SC1OH2
SODIUM CITRATEINACTIVE INGREDIENT1Q73Q2JULR2
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I2
SUCROSEINACTIVE INGREDIENTC151H8M5542
WATERINACTIVE INGREDIENT059QF0KO0R2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50383-58750383-587-66, 50383-587-16

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 11 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 11 · 608 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
GLYCERINGLYCERINPDC6A3C0OXLIQUID / TOPICAL2.5 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRABURSALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, EMULSION / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION, CONCENTRATE / INTRAVENOUS4000 mgExact identifier — unii candidate
59 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILOTION / TOPICAL21 mgExact identifier — unii candidate
174 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXCREAM, AUGMENTED / TOPICAL55 mgExact identifier — unii candidate
75 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MGEL / TRANSDERMAL7360 mgExact identifier — unii candidate
59 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SUPPOSITORY / RECTALNAExact identifier — unii candidate
48 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSHAMPOO / TOPICAL0.07 %w/wExact identifier — unii candidate
61 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR3.6 mgExact identifier — unii candidate
79 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MDROPS / NASAL10 mg/1mlExact identifier — unii candidate
59 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IMOUTHWASH / BUCCAL2 mg/1mlExact identifier — unii candidate
174 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / INTRAVESICAL7892 mgExact identifier — unii candidate
59 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXEMULSION / OPHTHALMIC3 mgExact identifier — unii candidate
75 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSUPPOSITORY / RECTAL440 mgExact identifier — unii candidate
75 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR0.35 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRALESIONALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION, SOLUTION / INTRAMUSCULAR25 mgExact identifier — unii candidate
61 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISYRUP / ORAL71 mg/5mlExact identifier — unii candidate
174 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSOLUTION/ DROPS / AURICULAR (OTIC)25 mgExact identifier — unii candidate
75 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXOINTMENT / TOPICALNAExact identifier — unii candidate
75 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / INTRAMUSCULAR0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / EXTRACORPOREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRA-AMNIOTICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSPRAY, METERED / NASAL1.2 mg/1mlExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLCAPSULE / ORAL131 mgExact identifier — unii candidate
61 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSUSPENSION / ORAL681 mgExact identifier — unii candidate
59 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / ORAL100 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSUSPENSION / TOPICAL0.24 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
SUCROSESUCROSEC151H8M554POWDER, FOR SUSPENSION / ORAL40017 mgExact identifier — unii candidate
48 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSUSPENSION / SUBCUTANEOUS0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRAVENOUS78 mgExact identifier — unii candidate
174 equally ranked IID candidates
SUCROSESUCROSEC151H8M554CONCENTRATE / ORAL4800 mgExact identifier — unii candidate
48 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSHAMPOO / TOPICAL0.03 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXTABLET, EXTENDED RELEASE / ORAL7 mgExact identifier — unii candidate
75 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MLIQUID / INTRAMUSCULAR400 mgExact identifier — unii candidate
59 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISWAB / TOPICAL0.01 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBCUTANEOUS1 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLLIQUID / INTRAVENOUS18 mgExact identifier — unii candidate
61 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSHAMPOO / TOPICAL714 mgExact identifier — unii candidate
59 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / RECTAL0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
SUCROSESUCROSEC151H8M554GRANULE / ORALNAExact identifier — unii candidate
48 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION / SUBCUTANEOUS2 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION/ DROPS / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCREAM, AUGMENTED / TOPICAL2 mgExact identifier — unii candidate
68 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGEL / TOPICAL70 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET / ORAL10 mgExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHLOTION / TOPICAL140 mgExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / RESPIRATORY (INHALATION)0.01 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
SUCROSESUCROSEC151H8M554INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS900 mgExact identifier — unii candidate
48 equally ranked IID candidates
CARBOXYMETHYLCELLULOSE SODIUMCARBOXYMETHYLCELLULOSE SODIUMK679OBS311FILM / BUCCAL18 mgExact identifier — unii candidate
44 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXINJECTION / INTRAVENOUS33750 mgExact identifier — unii candidate
75 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSOLUTION / NASAL25 mg/1mlExact identifier — unii candidate
75 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSUSPENSION / RECTAL904 mgExact identifier — unii candidate
61 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MSOLUTION / TOPICAL2445 mgExact identifier — unii candidate
59 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCONCENTRATE / ORAL12 mgExact identifier — unii candidate
79 equally ranked IID candidates
ALCOHOLALCOHOL3K9958V90MGEL, METERED / TRANSDERMAL3675 mgExact identifier — unii candidate
59 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A064042-001NYSTATINNYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28c2088c7a36db…
2026-09-14 22:38:342026-08A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-2884e616aacf4f…
2026-08-18 06:07:402026-07A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-2831067a03dcf5…
2025-08-23 18:47 UTC2025-08A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-286a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-2803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-282680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-285bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-2879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-281e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-288072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-285c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-285d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-284b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-2874a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-28bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-28782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-2887673890dc5c…
2021-03-12 10:30 UTC2021-03A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-285aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-288869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-28c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-283f01610625f2…
2019-09-15 20:21 UTC2019-09A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-28b00525d2431f…
2019-07-19 19:46 UTC2019-07A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1994-02-28ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-286a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-281c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-289b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-283f0d92c62455…
2023-05-13 08:27 UTC2023-05A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-28053a50430f4f…
2023-01-26 05:58 UTC2023-01A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-283bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064042-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1994-02-283a93d1ddd44b…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064042-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064042-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064042-001AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064042-001AA174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064042-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064042-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064042-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A064042-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064042-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064042-001AA1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064042-001AA13f01610625f2…
2019-09-15 20:21 UTC2019-09A064042-001AA1b00525d2431f…
2019-07-19 19:46 UTC2019-07A064042-001AA1ea99ee380514…
2022-09-29 23:25 UTC2022-09A064042-001AA1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A064042-001AA1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
9000d163-8d8d-4865-a30b-4a875330d95341c75856-4e15-4397-a6d4-c1193c0eb0e72022-05-25Adverse reactionsExact identifier
spl set id: 41c75856-4e15-4397-a6d4-c1193c0eb0e7

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.